Affiliations 

  • 1 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India
  • 2 Department of Pharmacognosy, Faculty of Pharmacy, Tishk International University, Erbil, 44001, KRG, Iraq
  • 3 Department of Research and Scientific Communications, Isthmus Research and Publishing House, New Delhi, 110044, India
  • 4 Department of Pharmaceutical Care, Rafha Central Hospital, Rafha 91911, Saudi Arabia
  • 5 Department of Clinical Pharmacy, General Administration of Pharmaceutical Care, Ministry of Health, Riyadh 11176, Saudi Arabia
  • 6 Department of Pharmaceutical Care, King Khalid Hospital in Majmaah, Riyadh Region 76312, Saudi Arabia
  • 7 College of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia
  • 8 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000, Kuala Lumpur, Malaysia
  • 9 School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India
  • 10 Innovative Medicines Group, Faculty of Health, Queensland University of Technology (QUT), Kelvin Grove, Brisbane, Queensland, 4059, Australia
  • 11 Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW, 2007, Australia
Curr Neuropharmacol, 2023;21(7):1558-1574.
PMID: 35950245 DOI: 10.2174/1570159X20666220810105421

Abstract

Quercetin (Qu), a dietary flavonoid, is obtained from many fruits and vegetables such as coriander, broccoli, capers, asparagus, onion, figs, radish leaves, cranberry, walnuts, and citrus fruits. It has proven its role as a nutraceutical owing to numerous pharmacological effects against various diseases in preclinical studies. Despite these facts, Qu and its nanoparticles are less explored in clinical research as a nutraceutical. The present review covers various neuroprotective actions of Qu against various neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, Huntington's, and Amyotrophic lateral sclerosis. A literature search was conducted to systematically review the various mechanistic pathways through which Qu elicits its neuroprotective actions and the challenges associated with raw Qu that compromise therapeutic efficacy. The nanoformulations developed to enhance Qu's therapeutic efficacy are also covered. Various ongoing/completed clinical trials related to Qu in treating various diseases, including NDs, are also tabulated. Despite these many successes, the exploration of research on Qu-loaded nanoformulations is limited mostly to preclinical studies, probably due to poor drug loading and stability of the formulation, time-consuming steps involved in the formulation, and their poor scale-up capacity. Hence, future efforts are required in this area to reach Qu nanoformulations to the clinical level.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.